Navigation Links
Viagra's hidden help for wildlife

Chinese men spurn traditional virility medicines

Chinese men are selectively switching from traditional Chinese medicine (TCM) to Viagra to treat erectile dysfunction, but sticking with tradition for ailments such as arthritis, indigestion and gout, according to new research published in Environmental Conservation.

The finding supports a prediction made by Australian and Alaskan researchers at the advent of Viagra's commercial release in 1998 that the new impotence drug might reduce demand for several animal species that are over-harvested to treat impotence with TCMs.

Animals such as seals, sea horses and tigers have long been hunted because practitioners of TCM use their body parts for their presumed healing and virility qualities.

The researchers surveyed 256 Chinese men, aged 50 to 76, who sought treatment at a large TCM clinic in Hong Kong. The men were questioned about their previous and current use of TCM and Western treatments for arthritis, indigestion, gout and impotence.

The study's lead authors are Dr Bill von Hippel, a psychologist from the University of New South Wales (Sydney, Australia), and his brother, Dr Frank von Hippel, a biologist from the University of Alaska, Anchorage. The von Hippels cite three key findings from the research.

"First, significantly more men had formerly used a TCM treatment for impotence than were current users," says Bill von Hippel.

"Second, they were significantly more likely to be using a Western treatment for impotence than a TCM treatment.

"Finally, among men who formerly used either Western or TCM treatments for impotence, they were more likely to switch from a TCM treatment to a Western drug than vice versa. In fact, nobody had switched from a Western drug to a TCM treatment for impotence.

"This was in contrast to their behaviour with the other three ailments - arthritis, indigestion and gout, where the men were more likely to be current users of a TCM treatment than a Western treatment.".

These findings stand in contrast to prior research suggesting a mistrust of Western medicine in Asian markets.

"When we proposed that Viagra might make inroads into TCM treatments for impotence, conservationists told us we were nave and that TCM consumers were unwilling to use a product outside their own medical tradition," says Bill von Hippel. "For example, there is still strong demand for tiger bone among TCM apothecaries who use it in the treatment of pain relief, despite the widespread availability of aspirin.

"But the failure to achieve an erection isn't comparable to having a headache or the many other ailments for which consumers still prefer TCM treatments. Furthermore, Viagra differs from many other Western drugs, in that the effects are rapid and visible to the naked eye.

"The fact is that prior to the commercial availability of Viagra in 1998, no product in any medical tradition had been proven to be an effective and non-intrusive treatment of erectile dysfunction. So despite their history of using traditional medicines and their alleged suspicions of Western medicine, the men we interviewed chose the product that works best."

These findings are consistent with previous research by the von Hippels showing evidence of a post-Viagra decline during the 1990s in the harvesting of three species used in TCM impotence treatments.

The pair attributed some of this decline to Viagra, despite scepticism among many academics and wildlife experts.

In 2002, the global market for TCM products and treatments was valued at more than $20 billion, according to the Chinese firm Shenzhen Matrix Information Consulting.


'"/>

Source:University of New South Wales


Related biology news :

1. Finding hidden invaders in a Hawaiian rain forest
2. UCLA cancer researchers shake loose hidden biomarker
3. Measuring hidden parasites in falciparum malaria
4. Envisat and ERS-2 reveal hidden side of Hurricane Rita
5. Computer modeling reveals hidden conversations within cells
6. Clues to breast cancer hidden inside stem cells
7. Squid skin reveals hidden messages
8. UBC researchers reveal dwarf aquatic plants hidden ancestry
9. Reading hidden intentions in the human brain
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:2/3/2017)... WASHINGTON , Feb. 3, 2017 A ... Identity Strategy Partners, LLP (IdSP) . Designed to ... in the complex identity market, founding partners Mark ... nearly 35 combined years just in identity expertise that ... tank and non-profit leadership. The Crego-Kephart combined expertise has ...
(Date:2/2/2017)... -- Central to its deep commitment to honor the ... Prize Foundation today announced the laureates of the ... in their respective fields of Life Sciences and ... recognized with the 2017 Japan Prize for original ... the advancement of science and technology, but also ...
(Date:1/30/2017)... 2017   Invitae Corporation (NYSE: ... companies, today announced that it will report its fourth ... guidance on Monday, February 13, 2017, and Invitae,s management ... 4:45 p.m. Eastern / 1:45 p.m. Pacific. ... review financial results, guidance, and recent developments and will ...
Breaking Biology News(10 mins):
(Date:2/17/2017)... According to a new ... Service), Type (Safety, Efficacy, Validation), Disease Indication (Cancer, ... Development, Disease-Risk) - Global Forecast to 2021" published ... USD 53.34 Billion by 2021 from USD 27.95 ... 13.8% during the forecast period (2016-2021). ...
(Date:2/17/2017)... Feb. 17, 2017  Protagonist Therapeutics, Inc. (NASDAQ: ... its oral peptide drug candidates, PTG-100 and PTG-200, ... European Crohn,s and Colitis Organization (ECCO).  The ECCO ... Spain from February 15 – 18, ... data on Protagonist drug candidates PTG-100 and PTG-200. ...
(Date:2/16/2017)... Calif. and GREENWICH, Conn. ... a private investment firm focused on venture growth ... the promotion of Josh Richardson , M.D. ... on investments in biotechnology companies.  He is a ... played important roles in Longitude,s investments in Aimmune ...
(Date:2/16/2017)... , Feb. 16, 2017   Capricor Therapeutics, ... clinical-stage biotechnology company developing first-in-class biological therapies for ... it has elected to terminate its license agreement ... receptor agonists, including Cenderitide. "Our decision ... as we prioritize our efforts to advance our ...
Breaking Biology Technology: